ANI Pharmaceuticals (ANIP) Competitors $56.91 +1.05 (+1.88%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ANIP vs. CNCE, PGNX, SELB, CTMX, DRRX, BHVN, BBIO, RARE, OGN, and IMVTShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Concert Pharmaceuticals (CNCE), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB), CytomX Therapeutics (CTMX), DURECT (DRRX), Biohaven (BHVN), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), and Immunovant (IMVT). These companies are all part of the "medical" sector. ANI Pharmaceuticals vs. Concert Pharmaceuticals Progenics Pharmaceuticals Selecta Biosciences CytomX Therapeutics DURECT Biohaven BridgeBio Pharma Ultragenyx Pharmaceutical Organon & Co. Immunovant ANI Pharmaceuticals (NASDAQ:ANIP) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, ANIP or CNCE? ANI Pharmaceuticals has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Which has higher valuation & earnings, ANIP or CNCE? ANI Pharmaceuticals has higher revenue and earnings than Concert Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$486.82M2.46$18.78M-$0.55-103.47Concert Pharmaceuticals$32.58M12.32-$80.05M-$3.21-2.61 Do analysts prefer ANIP or CNCE? ANI Pharmaceuticals presently has a consensus price target of $77.33, indicating a potential upside of 35.89%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Concert Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Concert Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in ANIP or CNCE? Concert Pharmaceuticals received 76 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. However, 64.48% of users gave ANI Pharmaceuticals an outperform vote while only 61.20% of users gave Concert Pharmaceuticals an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes43264.48% Underperform Votes23835.52% Concert PharmaceuticalsOutperform Votes50861.20% Underperform Votes32238.80% Do insiders & institutionals believe in ANIP or CNCE? 76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 70.6% of Concert Pharmaceuticals shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is ANIP or CNCE more profitable? Concert Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Concert Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% Concert Pharmaceuticals N/A -109.43%-76.65% Does the media refer more to ANIP or CNCE? In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Concert Pharmaceuticals. MarketBeat recorded 5 mentions for ANI Pharmaceuticals and 0 mentions for Concert Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.32 beat Concert Pharmaceuticals' score of 0.40 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ANI Pharmaceuticals Positive Concert Pharmaceuticals Neutral SummaryANI Pharmaceuticals beats Concert Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-103.4710.35102.4617.58Price / Sales2.46362.011,234.85158.43Price / Cash8.6852.6040.4736.33Price / Book2.9510.377.096.50Net Income$18.78M$153.60M$119.65M$226.22M7 Day Performance0.58%3.92%2.06%3.76%1 Month Performance-3.61%-6.78%-2.46%4.63%1 Year Performance10.06%33.23%33.95%29.20% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals4.2898 of 5 stars$56.91+1.9%$77.33+35.9%+10.1%$1.20B$486.82M-103.47642Positive NewsCNCEConcert PharmaceuticalsN/A$8.37flatN/AN/A$401.26M$32.58M-2.6164PGNXProgenics PharmaceuticalsN/A$4.10flatN/A+0.0%$355.05M$34.99M-5.1379Gap UpHigh Trading VolumeSELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Gap DownHigh Trading VolumeCTMXCytomX Therapeutics4.3893 of 5 stars$0.88+1.4%$5.77+556.9%-31.0%$68.77M$126.62M5.10170Gap UpDRRXDURECT3.0924 of 5 stars$0.94+9.0%$5.00+431.9%+55.4%$29.18M$8.55M-1.5680Analyst ForecastGap UpBHVNBiohaven3.8322 of 5 stars$46.79+3.5%$63.42+35.5%+50.7%$4.73B$462.51M-4.88239BBIOBridgeBio Pharma4.5819 of 5 stars$23.55+1.3%$47.57+102.0%-20.6%$4.45B$9.30M-9.64400Insider TradeNews CoverageRAREUltragenyx Pharmaceutical4.5863 of 5 stars$46.86+1.8%$87.46+86.6%+23.6%$4.33B$522.75M-7.111,276Analyst ForecastOGNOrganon & Co.4.7485 of 5 stars$15.32+2.9%$21.33+39.3%+35.9%$3.95B$6.26B2.9610,000IMVTImmunovant1.4585 of 5 stars$26.77+0.9%$48.10+79.7%-17.8%$3.93BN/A-11.95120Insider TradeNews Coverage Related Companies and Tools Related Companies Concert Pharmaceuticals Alternatives Progenics Pharmaceuticals Alternatives Selecta Biosciences Alternatives CytomX Therapeutics Alternatives DURECT Alternatives Biohaven Alternatives BridgeBio Pharma Alternatives Ultragenyx Pharmaceutical Alternatives Organon & Co. Alternatives Immunovant Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANIP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
